Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AKTS · NASDAQ · Pharmaceutical Preparations
$16.10−0.21 (−1.29%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
Aktis Oncology (AKTS) · oqro.io/stocks/AKTS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 16, 2026
T. Rowe Price Investment Management, Inc. now owns 6.2% of AKTS as a passive investorSourceFund moves · Holdings as of Sep 30, 2026 (Q3 2026) · Filed Nov 13, 2026
Soros Fund Management no longer reported AKTS for Q3 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
Ra Capital Management, L.P. disclosed a reduced position in AKTS for Q2 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Soros Fund Management disclosed a new position in AKTS for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
a16z Capital Management, L.L.C. disclosed a new position in AKTS for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Ra Capital Management, L.P. disclosed a new position in AKTS for Q1 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
RTW Investments, LP disclosed a new position in AKTS for Q1 2026Source